Washington University

University Health Network

The Medical College of Wisconsin, Inc.

John F Dipersio

Jeffrey A Medin

Allegra Petti

Murtaza S Nagree

Matthew Cooper

Matthew Christopher

Michael P Rettig

Timothy J Ley

The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.

Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors

Among the various aspects of the present disclosure is the provision of methods and compositions for upregulating MHC class II in cancer cells (e.g., a hematological cancer cell). Also provided are methods of treatment for subjects suffering from hematological cancers, comprising administration of interferon-&#x3b3; (IFN-&#x3b3;). The methods of treatment provided herein may be particularly suitable for subjects who have received an allogenic transplant or have suffered a relapse.

Methods and compositions for treatment of cancer

The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.

andenrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders

Growing community of inventors

St. Louis, MO, United States of America

John F Dipersio